Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines
Tae-Han Lee, Yeo-Jin Song, Hyoungyoung Kim, Yoon-Kyoung Sung, Soo-Kyung Cho
J Bone Metab. 2020;27(4):247-259.   Published online 2020 Nov 30     DOI: https://doi.org/10.11005/jbm.2020.27.4.247
Citations to this article as recorded by Crossref logo
Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study
M. Iki, K. Fujimori, S. Nakatoh, J. Tamaki, S. Ishii, N. Okimoto, K. Kamiya, S. Ogawa
Osteoporosis International.2022; 33(5): 1097.     CrossRef
Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan
Masayuki Iki, Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Kuniyasu Kamiya, Sumito Ogawa
Bone.2022; 160: 116396.     CrossRef
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club
Michaël R. Laurent, Stefan Goemaere, Charlotte Verroken, Pierre Bergmann, Jean-Jacques Body, Olivier Bruyère, Etienne Cavalier, Serge Rozenberg, Bruno Lapauw, Evelien Gielen
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho, Yoon-Kyoung Sung
Endocrinology and Metabolism.2021; 36(3): 536.     CrossRef
Understanding of Glucocorticoid Induced Osteoporosis
Chang-Nam Son
Keimyung Medical Journal.2021; 40(2): 69.     CrossRef